Cupid shares rally 8% after Q2 net profit jumps 133% YoY; company raises FY27-FY29 guidance

Shares of Cupid surged 7.75% to Rs 381.40 on Thursday after the company reported strong Q2FY27 results, with net profit rising 133% year-on-year (YoY) and revenue from operations increasing 122%. The stock also touched a fresh 52-week high of Rs 389 during the trading session.

Cupid reported revenue from operations of Rs 188 crore in the September quarter of FY27, registering a 122% increase from Rs 84 crore in the corresponding quarter of the previous financial year. The company’s net profit for the quarter surged 133% YoY to Rs 56 crore, compared with Rs 24 crore in the same quarter last year.

Cupid raises FY27, FY28 and FY29 guidance

Alongside its quarterly earnings, Cupid announced higher revenue and profitability targets for the coming financial years, reflecting its growth ambitions.

In its exchange filing, the company outlined the following guidance:

• FY27: Revenue of Rs 880 crore or more and net profit of Rs 275 crore or more.
• FY28: Revenue of Rs 1,305 crore or more and net profit of approximately Rs 390 crore.
• FY29: Revenue of Rs 1,950 crore or more and net profit of approximately Rs 605 crore.

Cupid also reported robust growth during the first half of FY27. Its total income increased 136% YoY to Rs 365.95 crore, while net profit climbed 156% to Rs 100.37 crore.

The domestic business contributed Rs 224.64 crore, accounting for 67% of H1FY27 sales, compared with 41% in FY26. The Consumer Healthcare & FMCG business was a key contributor, generating Rs 166.88 crore, equivalent to 49% of total sales. This highlights the increasing scale and contribution of the company’s consumer portfolio.

The international business contributed Rs 112.73 crore, representing 33% of H1FY27 sales. Growth was supported by institutional demand under the PFSCM agreement and supplies under South Africa’s 2025-30 national programme. Price revisions implemented across the export portfolio were also reflected in realisations throughout the first half.EBITDA for H1FY27 stood at Rs 114.83 crore, registering 156% YoY growth. The company continues to focus on strengthening its product mix, improving sourcing efficiencies and leveraging scale benefits as its Consumer Healthcare & FMCG business expands across organised retail channels.

Cupid expects H2FY27 to be significantly stronger than H1FY27, supported by additional manufacturing capacity and expansion in its retail distribution network.

The company’s Palava facility is expected to be commissioned in Q3FY27, adding manufacturing capacity. It also expects supplies to begin across V2 Retail’s more than 425 stores, alongside an expanding presence in the Style Baazar network.

Cupid share price performance and technical indicators

Cupid shares have delivered a massive rally of approximately 577% over the past year. The stock currently commands a market capitalisation of around Rs 48,407 crore.

According to Trendlyne technical data, Cupid is trading above all eight of its key simple moving averages (SMAs), indicating strength across multiple technical timeframes.

Promoters, FIIs and mutual funds increase stake

The September 2026 quarter shareholding pattern showed that promoters, foreign institutional investors (FIIs) and mutual funds increased their holdings in Cupid compared with the previous quarter.

• Promoters: Increased their stake to 47.69% in September 2026 from 46.24% in June 2026.
• FIIs: Raised their holding to 4.69% from 4.17%.
• Mutual funds: Increased their stake to 0.57% from 0.33%.

The increase in promoter and institutional shareholding, alongside strong earnings growth and higher financial guidance, adds to the key developments keeping Cupid shares in focus.

Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here